Auro Pharma Inc Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Auro Pharma Inc Pharmaceutical Import Records from India — 11 Products, $8.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Auro Pharma Inc — Pharmaceutical Importer Profile (2026) | 11 Products, $8.9M Trade | TransData Nexus

Auro Pharma Inc

Pharmaceutical Importer · Canada · CNS & Psychiatric Focus · $8.9M Total Trade · DGFT Verified

Auro Pharma Inc is a pharmaceutical importer based in Canada with a total trade value of $8.9M across 11 products in 4 therapeutic categories. Based on 229 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Auro Pharma Inc sources from 3 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 91.1% of imports.

Auro Pharma Inc — Import Portfolio & Supplier Network

Auro Pharma Inc import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Auro Pharma Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$62.0M	2,781	91.1%
Eugia Pharma Specialities Limited	$5.7M	152	8.4%
Apl Healthcare Limited

What Formulations Does Auro Pharma Inc Import?

Formulation	Value	Ships
Metformin tablets 500MG(auro-metformin	$1.3M	31
Venlafaxine 150 MG capsules(auro-venlafa	$1.2M	27
Venlafaxine hydrochloride extended	$1.1M	25
Clindamycin hydrochloride capsules 300MG	$843.7K	18
Quetiapine fumarate tablets	$600.0K	12
Amoxicillin for oral suspension USP	$547.9K	39
Amoxicillin & clavulanate potassium	$496.6K	11
Pantoprazole sodium for injection 40 MG	$468.8K	11
Clopidogrel tablets 75MG(auro-clopidogre	$464.6K	10
Venlafaxine capsules 75MG	$446.9K	12
Sertraline 100MG capsules(auro-sertralin	$397.0K	12
Cephalexin tablets 500 MG	$377.5K	9
Gabapentin capsules 400MG(auro-gabapenti	$351.5K	11
Amoxixillin & clavulanate potassium	$330.4K	7
Atorvastatin 40 MG tablets(auro-atorvast	$320.0K	12

Auro Pharma Inc imports 1,608 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sertraline	CNS & Psychiatric	$2.6M	53	0.5%	12
2	Cefixime	Advanced Antibiotics	$1.6M	32	0.5%	15
3	Dapagliflozin	Advanced Diabetes Medications	$1.3M	59	2.7%	8
4	Escitalopram	CNS & Psychiatric	$950.0K	19	0.5%	17
5	Ertapenem	Advanced Antibiotics	$650.0K	13	0.6%	13
6	Repaglinide	Advanced Diabetes Medications	$503.4K	29	3.7%	10
7	Piperacillin	Advanced Antibiotics	$500.0K	10	0.6%	18
8	Acyclovir	Antivirals	$250.0K	5	0.2%	16
9	Sulfamethoxazole	Advanced Antibiotics	$150.0K	3	0.8%	13
10	Trimethoprim	Advanced Antibiotics	$150.0K	3	0.6%	17
11	Valacyclovir	Antivirals	$150.0K	3	0.2%	12

Auro Pharma Inc imports 11 pharmaceutical products across 4 categories into Canada totaling $8.9M.

Auro Pharma Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Auro Pharma Inc. is a Canadian subsidiary of Aurobindo Pharma Ltd., a leading global generic pharmaceutical company headquartered in India. Established in 2004, Auro Pharma Inc. has rapidly emerged as one of Canada's fastest-growing generic pharmaceutical firms. The company specializes in the research, development, and manufacturing of drug intermediates, Active Pharmaceutical Ingredients (APIs), and finished formulations. Auro Pharma Inc. offers a distinct advantage to customers through its robust global manufacturing capabilities, efficient supply chain management, and a focus on developing and supplying a wide range of generic products. (auropharma.ca)

As of January 2023, Auro Pharma Inc. has surpassed 200 Notice of Compliance (NOC) approvals in Canada, reflecting its commitment to expanding its product portfolio and entering specialty segments. The company's product offerings include a diverse range of generic formulations, encompassing therapeutic areas such as cardiovascular diseases, diabetes, and central nervous system disorders. Auro Pharma Inc. continues to submit new product dossiers, aiming to provide cost-effective generic alternatives in both public and private healthcare sectors.

2Distribution Network

Auro Pharma Inc. operates a distribution center located at 3700 Steeles Avenue West, Suite #402, Woodbridge, Ontario, L4L 8K8, Canada. The company has expanded its distribution capabilities by opening a second center in Calgary, Alberta, in January 2022. (auropharma.ca) These facilities enable Auro Pharma Inc. to efficiently manage its logistics and supply chain operations across Canada, ensuring timely delivery of pharmaceutical products to hospitals, retail pharmacies, and healthcare providers nationwide.

3Industry Role

Auro Pharma Inc. functions as a pharmaceutical importer and distributor within Canada's supply chain. By sourcing finished pharmaceutical formulations from its parent company, Aurobindo Pharma Ltd., and other suppliers, Auro Pharma Inc. plays a pivotal role in providing cost-effective generic medications to the Canadian market. The company's focus on obtaining a large portfolio of product approvals and its efficient supply chain management underscore its significant position in the industry. (auropharma.ca)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Auro Pharma Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Auro Pharma Inc. demonstrates a high degree of supplier concentration, with 91.1% of its imports from India sourced from Aurobindo Pharma Ltd. This strategic choice leverages the parent company's extensive manufacturing capabilities and regulatory expertise. The remaining 8.4% of imports are from Eugia Pharma Specialities Ltd., indicating a reliance on a limited number of suppliers. While this concentration can lead to favorable pricing and streamlined logistics, it also exposes Auro Pharma Inc. to potential risks associated with supply chain disruptions or changes in supplier dynamics. The stability of this relationship is crucial for maintaining consistent product availability and market competitiveness.

2Supply Chain Resilience

Auro Pharma Inc.'s supply chain resilience is closely tied to its reliance on Aurobindo Pharma Ltd. and Eugia Pharma Specialities Ltd. The company's focus on finished pharmaceutical formulations, with a portfolio of 1,608 unique formulations, suggests a diversified product range that can mitigate risks associated with individual product shortages. However, the heavy dependence on a limited number of suppliers may pose challenges in the event of supply chain disruptions. To enhance resilience, Auro Pharma Inc. could consider diversifying its supplier base and establishing relationships with additional manufacturers to ensure a more robust supply chain.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada. The Food and Drugs Act and its associated regulations govern the importation, distribution, and sale of pharmaceutical products in the country. Health Canada's Notice of Compliance (NOC) is required for the marketing authorization of pharmaceutical products, ensuring they meet the necessary safety, efficacy, and quality standards. For Indian generics to enter the Canadian market, they must undergo this regulatory process to obtain NOC approval.

2Import Licensing & GMP

Import licensing requirements in Canada stipulate that pharmaceutical products must be authorized by Health Canada before they can be imported and sold. Manufacturers must provide evidence of Good Manufacturing Practice (GMP) compliance, which can be demonstrated through certifications such as EU GMP, WHO GMP, or PIC/S. These certifications ensure that manufacturing processes meet international quality standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Canada.

3Quality & Labeling

Auro Pharma Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Auro Pharma Inc.'s focus on importing products in the Central Nervous System (CNS) & Psychiatric, Advanced Antibiotics, and Advanced Diabetes Medications categories aligns with significant market demand in Canada. The company's top five imported products—Sertraline, Cefixime, Dapagliflozin, Escitalopram, and Ertapenem—address prevalent health conditions such as depression, bacterial infections, diabetes, and other chronic diseases. This strategic product selection positions Auro Pharma Inc. to meet critical healthcare needs within the Canadian market.

2Sourcing Profile

Auro Pharma Inc. primarily sources generic drugs from India, leveraging the manufacturing capabilities of Aurobindo Pharma Ltd. and Eugia Pharma Specialities Ltd. The company's focus on finished pharmaceutical formulations, with a portfolio of 1,608 unique formulations, indicates a preference for ready-to-market products that meet Canadian regulatory standards. India's established pharmaceutical manufacturing sector, known for its compliance with international GMP standards, makes it a strategic sourcing partner for Auro Pharma Inc.

3Market Positioning

Seller's Guide — How to Become a Supplier to Auro Pharma Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Auro Pharma Inc., given the company's reliance on a limited number of suppliers. By offering competitive pricing, reliable supply, and compliance with Canadian regulatory standards, Indian exporters can position themselves as viable alternatives to existing suppliers. Identifying gaps in Auro Pharma Inc.'s current sourcing, such as unmet therapeutic needs or product shortages, can further enhance the attractiveness of new suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply Auro Pharma Inc. and the Canadian market must obtain GMP certifications recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S. Additionally, they must ensure that their products meet Health Canada's safety, efficacy, and quality standards, as evidenced by obtaining NOC approvals. Compliance with labeling requirements in both English and French is also essential.

3How to Approach

Frequently Asked Questions — Auro Pharma Inc

What products does Auro Pharma Inc import from India?

Auro Pharma Inc imports 11 pharmaceutical products across 4 categories. Top imports: Sertraline ($2.6M), Cefixime ($1.6M), Dapagliflozin ($1.3M), Escitalopram ($950.0K), Ertapenem ($650.0K).

Who supplies pharmaceuticals to Auro Pharma Inc from India?

Auro Pharma Inc sources from 3 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (91.1% of imports, $62.0M).

What is Auro Pharma Inc's total pharmaceutical import value?

Auro Pharma Inc's total pharmaceutical import value from India is $8.9M, based on 229 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Auro Pharma Inc focus on?

Auro Pharma Inc imports across 4 categories. The largest: CNS & Psychiatric (40.5%), Advanced Antibiotics (34.3%), Advanced Diabetes Medications (20.6%).

Get Full Auro Pharma Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.